791 related articles for article (PubMed ID: 25537576)
1. Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids.
Pryce G; Riddall DR; Selwood DL; Giovannoni G; Baker D
J Neuroimmune Pharmacol; 2015 Jun; 10(2):281-92. PubMed ID: 25537576
[TBL] [Abstract][Full Text] [Related]
2. Combination of cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome.
Al-Ghezi ZZ; Busbee PB; Alghetaa H; Nagarkatti PS; Nagarkatti M
Brain Behav Immun; 2019 Nov; 82():25-35. PubMed ID: 31356922
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
Rice J; Cameron M
Curr Neurol Neurosci Rep; 2018 Jun; 18(8):50. PubMed ID: 29923025
[TBL] [Abstract][Full Text] [Related]
4. Combination of Cannabinoids, Δ9- Tetrahydrocannabinol and Cannabidiol, Ameliorates Experimental Multiple Sclerosis by Suppressing Neuroinflammation Through Regulation of miRNA-Mediated Signaling Pathways.
Al-Ghezi ZZ; Miranda K; Nagarkatti M; Nagarkatti PS
Front Immunol; 2019; 10():1921. PubMed ID: 31497013
[TBL] [Abstract][Full Text] [Related]
5. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Use of Δ9-THC and Cannabidiol: Evaluation of a New Extraction Procedure for the Preparation of Cannabis-based Olive Oil.
Morini L; Porro G; Liso M; Groppi A
Curr Pharm Biotechnol; 2017; 18(10):828-833. PubMed ID: 29189144
[TBL] [Abstract][Full Text] [Related]
7. Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis.
Al-Izki S; Pryce G; Hankey DJ; Lidster K; von Kutzleben SM; Browne L; Clutterbuck L; Posada C; Edith Chan AW; Amor S; Perkins V; Gerritsen WH; Ummenthum K; Peferoen-Baert R; van der Valk P; Montoya A; Joel SP; Garthwaite J; Giovannoni G; Selwood DL; Baker D
Brain; 2014 Jan; 137(Pt 1):92-108. PubMed ID: 24287115
[TBL] [Abstract][Full Text] [Related]
8. New perspectives in the studies on endocannabinoid and cannabis: abnormal behaviors associate with CB1 cannabinoid receptor and development of therapeutic application.
Fujiwara M; Egashira N
J Pharmacol Sci; 2004 Dec; 96(4):362-6. PubMed ID: 15599103
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.
Rosenberg EC; Patra PH; Whalley BJ
Epilepsy Behav; 2017 May; 70(Pt B):319-327. PubMed ID: 28190698
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been ….
Baron EP
Headache; 2015 Jun; 55(6):885-916. PubMed ID: 26015168
[TBL] [Abstract][Full Text] [Related]
11. Cannabinoids in clinical practice.
Williamson EM; Evans FJ
Drugs; 2000 Dec; 60(6):1303-14. PubMed ID: 11152013
[TBL] [Abstract][Full Text] [Related]
12. The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ9-tetrahydrocannabinol acting through CB1 receptors.
Moreno-Martet M; Feliú A; Espejo-Porras F; Mecha M; Carrillo-Salinas FJ; Fernández-Ruiz J; Guaza C; de Lago E
Mult Scler Relat Disord; 2015 Nov; 4(6):505-11. PubMed ID: 26590655
[TBL] [Abstract][Full Text] [Related]
13. Pharmacology of cannabinoids in the treatment of epilepsy.
Gaston TE; Friedman D
Epilepsy Behav; 2017 May; 70(Pt B):313-318. PubMed ID: 28087250
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of a novel cannabinoid agent CB52 in the mouse model of experimental autoimmune encephalomyelitis.
Ribeiro R; Yu F; Wen J; Vana A; Zhang Y
Neuroscience; 2013 Dec; 254():427-42. PubMed ID: 24036373
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals.
Legare CA; Raup-Konsavage WM; Vrana KE
Pharmacology; 2022; 107(3-4):131-149. PubMed ID: 35093949
[TBL] [Abstract][Full Text] [Related]
16. Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances.
Smith PF
Expert Rev Neurother; 2007 Sep; 7(9):1157-63. PubMed ID: 17868014
[TBL] [Abstract][Full Text] [Related]
17. Cannabinoids in the treatment of pain and spasticity in multiple sclerosis.
Smith PF
Curr Opin Investig Drugs; 2002 Jun; 3(6):859-64. PubMed ID: 12137404
[TBL] [Abstract][Full Text] [Related]
18. Cannabis and Cannabinoids in Multiple Sclerosis: From Experimental Models to Clinical Practice-A Review.
Sirbu CA; Georgescu R; Pleşa FC; Paunescu A; Marilena Ţânţu M; Nicolae AC; Caloianu I; Mitrica M
Am J Ther; 2023 May; 30(3):e220-e231. PubMed ID: 37278703
[TBL] [Abstract][Full Text] [Related]
19. Current status of cannabis treatment of multiple sclerosis with an illustrative case presentation of a patient with MS, complex vocal tics, paroxysmal dystonia, and marijuana dependence treated with dronabinol.
Deutsch SI; Rosse RB; Connor JM; Burket JA; Murphy ME; Fox FJ
CNS Spectr; 2008 May; 13(5):393-403. PubMed ID: 18496477
[TBL] [Abstract][Full Text] [Related]
20. The legal status of cannabis (marijuana) and cannabidiol (CBD) under U.S. law.
Mead A
Epilepsy Behav; 2017 May; 70(Pt B):288-291. PubMed ID: 28169144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
